Changyu He

ORCID: 0000-0001-9867-9629
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Nanoparticle-Based Drug Delivery
  • Gastrointestinal Tumor Research and Treatment
  • Intraperitoneal and Appendiceal Malignancies
  • Advanced Polymer Synthesis and Characterization
  • Metastasis and carcinoma case studies
  • Cancer-related molecular mechanisms research
  • Nanoplatforms for cancer theranostics
  • RNA Interference and Gene Delivery
  • Cancer-related gene regulation
  • RNA modifications and cancer
  • Cancer Cells and Metastasis
  • HIV Research and Treatment
  • Advanced biosensing and bioanalysis techniques
  • Epigenetics and DNA Methylation
  • Colorectal and Anal Carcinomas
  • Dendrimers and Hyperbranched Polymers
  • Cancer-related Molecular Pathways
  • Peptidase Inhibition and Analysis
  • RNA Research and Splicing
  • Fibroblast Growth Factor Research
  • HIV/AIDS drug development and treatment
  • Nanocluster Synthesis and Applications
  • Developmental Biology and Gene Regulation
  • TGF-β signaling in diseases

Ruijin Hospital
2015-2024

Shanghai Jiao Tong University
2015-2024

Zhejiang University of Technology
2024

Shanghai Institute of Hematology
2014-2016

First Hospital of China Medical University
2009

Chengdu Medical College
2006

Abstract Background N6-methyladenosine (m6A) is the most prevalent RNA epigenetic regulation in eukaryotic cells. However, understanding of m6A colorectal cancer (CRC) very limited. We designed this study to investigate role CRC. Methods Expression level METTL14 was extracted from public database and tissue array clinical relevance Next, gain/loss function experiment used define progression Moreover, transcriptomic sequencing (RNA-seq) applied screen potential targets METTL14. The specific...

10.1186/s12943-020-1146-4 article EN cc-by Molecular Cancer 2020-02-28

Abstract Long noncoding RNA UCA1 has emerged as a novel regulator in cancer initiation and progression of various cancers. However, function underlying mechanism the gastric (GC) remain unclear. In present study, we report that expressed highly GC tissues cells, which was partly induced by SP1. promoted cell proliferation G1/S transition vitro vivo . Moreover, exerted its through interacting with EZH2, promoting direct interaction cyclin D1 promoter to activate translation D1. Furthermore,...

10.1038/cddis.2017.143 article EN cc-by Cell Death and Disease 2017-06-01

// Jie Huang 1 , Li Zhang Changyu He Ying Qu Jianfang Jianian Tao Du Xuehua Chen Yingyan Yu Bingya Liu and Zhenggang Zhu Shanghai Key Laboratory of Gastric Neoplasms, Department Surgery, Institute Digestive Ruijin Hospital, Jiao Tong University School Medicine, Shanghai, China Correspondence: Liu, email: Zhu, Keywords : Claudin-1, Anoikis, β-catenin, cancer Received August 14, 2014 Accepted December 01, Published 02, Abstract Claudin-1 (CLDN1) is overexpressed in gastric correlated with...

10.18632/oncotarget.2936 article EN Oncotarget 2014-12-02

Abstract Adenosine triphosphate (ATP) in the tumor microenvironment serves a vital role during progression. ATP synthase F1 β subunit (ATP5B) is one of most important subunits and increases cellular levels. ATP5B reportedly participates carcinogenesis several tumors. However, regulatory mechanisms remain poorly understood gastric cancer (GC). Here, we determined that high expression tissues GC positively correlated with age, size, TNM stage, lymph node metastasis, patients’ poor prognosis....

10.1096/fj.202000608r article EN cc-by-nc-nd The FASEB Journal 2021-03-14

The aim of this study to develop galactosylated erlotinib liposomes for treatment lung cancer. were prepared by using solvent evaporation method. Various parameters such as particle size, zeta potential, entrapment efficiency, stability and in vitro drug release determined. size (both conventional modified) was 103.5 121.4 nm. potential EE both -7.1 ± 1.3 mV, -1.2 0.5 mV (82.3 1.9)%, (83.4 1.5)%, respectively. It found that modified increase the particles. results indicated from similar...

10.1080/21691401.2017.1396222 article EN Artificial Cells Nanomedicine and Biotechnology 2017-10-28

// Qing Chang 1, 2, * , Li Zhang 4, Changyu He 1 Baogui Jun 2 Bingya Liu Naiyan Zeng 3 Zhenggang Zhu Department of Surgery, Shanghai Key Laboratory Gastric Neoplasms, Institute Digestive Ruijin Hospital, Jiao Tong University School Medicine, Shanghai, China Clinical Oncology, Pathology and Pathophysiology, laboratory Cell Differentiation Apoptosis Chinese Ministry Education, 4 Current Address: Gastrointestinal Guizhou Provincial People's Guiyang, These authors have contributed equally to...

10.18632/oncotarget.5814 article EN Oncotarget 2015-10-23

Abstract Background Data on the long-term oncological outcomes of patients who undergo conversion surgery (CS) in gastric cancer (GC) with peritoneal metastasis (PM) are limited. Methods GC PM received intraperitoneal (ip) and systemic chemotherapy between April 2015 January 2021 were enrolled. Multivariate analysis was performed to identify risk factors associated survival. Clinicopathological survival compared those CS without (NCS). The paclitaxel (PTX) plus tegafur–gimeracil–oteracil...

10.1007/s10120-023-01452-8 article EN cc-by Gastric Cancer 2023-12-24

// Li-yun Yang 1 , Chang-yu He 2 Xue-hua Chen Li-ping Su Bing-ya Liu Hao Zhang Department of Otolaryngology, Ruijin Hospital, School Medicine, Shanghai Jiaotong University, Shanghai, China Key Laboratory Gastric Neoplasms, Institute Digestive Surgery, Correspondence to: Zhang, email: zhanghaoent@163.com Keywords: laryngeal cancer, aurora kinase A, FAK, PI3K, Akt Received: December 29, 2015 Accepted: June 09, 2016 Published: 23, ABSTRACT Revival dormant tumor cells may be an important...

10.18632/oncotarget.10233 article EN Oncotarget 2016-06-23

The prognosis of advanced gastric cancer (GC) invading the serosa remains poor, mainly owing to high incidence peritoneal recurrence. Patients with metastases are often treated neoadjuvant intraperitoneal and systemic chemotherapies (NIPS). Good responders NIPS undergo conversion gastrectomy. This study aims explore biomarkers predicting occurrence metastasis (PM) evaluating efficacy in GC patients.We collected six lavage (PL) samples from two patients PM, without diminished PM after via...

10.1007/s10120-023-01368-3 article EN other-oa Gastric Cancer 2023-02-04

Multi-block copolymers, which are composed of two or more covalent interconnected polymeric segments different types, offer unparalleled opportunities for designing new nanostructured materials with enhanced functionality and properties.

10.1039/c6py00326e article EN Polymer Chemistry 2016-01-01

Background Preoperative chemotherapy (PCT) has been considered an important treatment for advanced gastric cancer (AGC). The tumor regression grade (TRG) system is effective tool the assessment of patient responses to PCT. Pathological complete response (TRG = 0) primary excellent predictor better prognosis. However, which patients could achieve pathological after still unknown. study aimed find predictors TRG 0 in AGC. Methods A total 304 with from July 2009 November 2018 were enrolled...

10.3389/fonc.2021.607640 article EN cc-by Frontiers in Oncology 2021-04-15

In this study, we tried to access the efficacy and safety of oxaliplatin plus S-1 with intraperitoneal paclitaxel (PTX) for treatment Chinese advanced gastric cancer peritoneal metastases.Thirty patients diagnosed underwent laparoscopic exploration were enrolled when macroscopic disseminated metastases (P1) confirmed. PTX was diluted in 1 l normal saline IP administered through port at an initial dose 40 mg/m2 over h on day1,8, respectively. Oxaliplatin intravenously 100 day1, orally 80 14...

10.1186/s12885-021-09027-5 article EN cc-by BMC Cancer 2021-12-01

// Changyu He 1,* , Zhenqiang Wang Li Zhang 1 Liyun Yang 2 Jianfang Xuehua Chen Jun 3 Qing Chang 4 Yingyan Yu Bingya Liu and Zhenggang Zhu Shanghai Key Laboratory of Gastric Neoplasms, Department Surgery, Institute Digestive Ruijin Hospital, Jiao Tong University School Medicine, Shanghai, China Otolaryngology, Clinical Oncology, Research Center, Jiading District Central Hospital Affiliated Medicine & Health Sciences, * These authors have contributed equally to this work Correspondence...

10.18632/oncotarget.17473 article EN Oncotarget 2017-04-27

Although recent advances in systemic chemotherapy have improved the clinical outcomes of gastric cancer patients with peritoneal metastasis, peritoneum still represents a common site treatment failure and disease recurrence. Neoadjuvant intraperitoneal–systemic has been acknowledged as more aggressive for metastasis. In this multicenter phase III randomized controlled trial, 238 will be randomly separated into two groups 2:1 ratio after laparoscopic exploration. The experimental arm receive...

10.2217/fon-2021-1414 article EN cc-by-nc-nd Future Oncology 2022-02-04

Gastric cancer (GC) is one of the most common cancers and second leading cause deaths in world. Many factors have been reported regarding progression development GC. In this study, we aimed to investigate correlation 3-phosphoinositide dependent protein kinase-1 (PDK-1) with cell viability, migration, invasion The expression PDK-1 was measured different GC lines. Thereafter, interfered by small hairpin RNA (shRNA) then incubated or without inhibitor nuclear factor-B (NF-B) pyrrolidine...

10.3727/096504017x14845839228545 article EN Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2017-01-21

Background: Gastric cancer (GC) with peritoneal metastasis has an extremely poor prognosis.Paclitaxel (PTX) intraperitoneal infusion provides effective treatment for these patients.However, GC patients who receiving PTX treatments tend to occur PTX-resistance accompany more aggressive ascites and metastasis.How does this happen is still unknown.Here, we aimed explore the mechanisms that mediate in metastasis.Methods: Ascites samples were collected before after relapse 3 patients.To determine...

10.7150/jca.48193 article EN cc-by-nc Journal of Cancer 2020-11-06
Coming Soon ...